Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general financial performance.
Material Changes
On June 6, 2014, a revaluation of the cash element of the notional investment held within the GSK 401K plan resulted in an increase in the notional allocation of American Depositary Shares (ADSs). The transaction occurred at a price of $53.70 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Transaction Date: June 6, 2014.
- Instrument: GSK American Depositary Shares (ADSs).
- Transaction Price: $53.70 per ADS.
- Beneficiary: Dr. K. Slaoui (Connected Person of Director Dr. M. Slaoui).
- Quantity: 4 ADSs allocated to the connected person.
- Director Allocation: Dr. M. Slaoui received 0 ADSs in this specific transaction.